Contineum Therapeutics
CTNM
102 hedge funds and large institutions have $501M invested in Contineum Therapeutics in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 15 closing their positions.
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
68% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 19
25% more capital invested
Capital invested by funds: $399M → $501M (+$102M)
13% more funds holding
Funds holding: 90 → 102 (+12)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.17% less ownership
Funds ownership: 93.52% → 93.34% (-0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$18.3M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.39M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.26M |
| 5 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$18.6M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$16.9M |
| 3 |
Millennium Management
New York
|
-$7.92M |
| 4 |
JHC
Jones Hill Capital
New York
|
-$6.7M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.88M |
CTNM Hedge Fund Activity: Q2 2026 in Review
102 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q2 2026, worth a combined $501M — up 25% from $399M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CTNM positions and 15 closed out — a net gain of 14 holders — while 32 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $18.3M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $18.6M sold.
- 102 institutional investors held Contineum Therapeutics (CTNM) as of Q2 2026, up from 90 in Q1 2026.
- Funds reported $501M of Contineum Therapeutics stock for Q2 2026, up 25% quarter-over-quarter.
- 29 funds opened new Contineum Therapeutics positions in Q2 2026 and 15 closed out, a net change of +14 holders.
- The largest Contineum Therapeutics buyer in Q2 2026 was BlackRock, an estimated $18.3M added.
- The largest Contineum Therapeutics seller in Q2 2026 was Baker Bros. Advisors, an estimated $18.6M sold.
Based on aggregated 13F filings for Q2 2026.